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HIGHLIGHTS 
• Temporal changes have been found in atrial fibrillation (AF) epidemiology 
• AF patients re becoming older and more burdened with comorbidities 
• Use of oral anticoagulant (OAC) drugs increased over the last decade in Europe 
• OAC use is associated with a reduction in thromboembolic and cardiovascular events 
• Despite the increased OAC use, a high risk of cardiovascular death still persists.  
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ABSTRACT 
Background: In 2002, the European Society of Cardiology conducted the Euro Heart Survey 
(EHS), while in 2014concluded 1-year follow-up of the EURObservational Research 
Programme AF (EORP-AF) Pilot Registry.   
Methods: We analysed differences in clinical profiles, therapeutic approaches and outcomes 
between these two cohorts after propensity score matching (PSM). 
Results: After PSM, 5206 patients were analysed. In EORP-AF there were more elderly 
patients than EHS (p<0.001). EORP-AF patients were more burdened with cardiovascular 
(CV) and non-CV comorbidities, with a higher proportion of patients with high 
thromboembolic risk. EORP-AF patients used more oral-anticoagulant (OAC) (p<0.001). 
At 1-year follow-up EORP-AF patients had lower risk for thromboembolic and CV events, 
readmission for AF and other CV reasons (all p<0.001), showing conversely a higher risk for 
CV death (p=0.015). Kaplan-Meier curves showed that EORP-AF patients had higher risk for 
CV death (p<0.0001) and all-cause death (p=0.0019). Cox regression confirmed that EORP-
AF patients were at higher risk for CV death (p=0.021). 
Conclusions: We found significant changes in AF epidemiology over a decade in Europe, 
with older patients, more burdened with comorbidities. A greater use of OAC was found. 
Despite a reduction in risk for thromboembolic events, a high risk of CV-related death was 
still evident. 
 
KEYWORDS: atrial fibrillation; epidemiology; Europe; thromboembolic risk; mortality.  
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1. INTRODUCTION 
 
Atrial fibrillation (AF) is the most common arrhythmia worldwide[1]. In 2010 an estimated 
33 million people were affected by AF, with an estimated prevalence (per 100,000 
population) of 596.2 in men and 373.1 in women, progressively increasing from 1990 in both 
males and females, as well as in both developed and developing countries[2]. Similarly, age-
adjusted AF incidence increased in both males and females from 1990 to 2010[2]. In Europe, 
one out of 4 middle-aged adults will suffer with AF, with up to 17 million subjects projected 
to be diagnosed by 2030[1]. 
 
AF is associated with a significant risk of ischemic stroke, death and other cardiovascular 
events[1,3] Over the last 20 years, AF-related deaths have been progressively increasing both 
in male and female patients, as well as in developed and developing countries[2]. Also, recent 
data have reported changes over time in the clinical profile of AF patients, impacting on 
clinical outcomes[4]. 
 
Oral anticoagulant (OAC) therapy is central to AF management, resulting in a significant 
reduction in thromboembolic risk[1]. The landscape of stroke prevention in AF has also 
changed after the introduction of non-vitamin K antagonist oral anticoagulants as an effective 
and safe alternative to vitamin K antagonists[1].  In a systematic review of AF registries, the 
overall risk of death was showed to be persistently high, despite an increase in OAC use[5]. 
 
In 2003, the European Society of Cardiology conducted the Euro Heart Survey on AF (EHS) 
a prospective registry about AF management in Europe[6]. After approximately 10 years, the 
ESC then conducted the EURObservational Research Programme in AF (EORP-AF) Pilot 
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Registry[7], which described contemporary management of AF patients by European 
cardiologists and to ascertain European Society of Cardiology guideline implementation for 
stroke prevention in AF. 
 
We hypothesised temporal differences in clinical and risk profiles, therapeutic approaches 
and outcomes between AF patients enrolled in EORP-AF and EHS. Our aim was to perform 
a post-hoc comparison between EHS and EORP-AF to describe differences in baseline 
characteristics, comorbidities, clinical management and thromboembolic risk, as well as 
outcomes after 1-year of follow-up. 
 
2. METHODS 
 
2.1 Study Cohort 
The EORP-AF Pilot Registry is a prospective, observational, multicentre study, held by 
European Society of Cardiology in 9 members countries, about AF patients in cardiology 
practice. The study enrolled, from 67 enrolling centres, consecutive patients presenting with 
AF as primary or secondary diagnosis to in- and outpatients cardiology services from 
February 2012 to March 2013. The qualifying AF event was recorded by a 12-lead ECG, 24 
h ECG Holter or other electrocardiographic documentation within 12 months before 
enrolment. A follow-up observation period was planned at 1, 2 and 3 years after enrolment. 
Details about study protocol and main results have been reported elsewhere[7–9].  
 
Similarly, the EHS on AF was a prospective, observational, multicentre study conducted by 
the European Society of Cardiology in 35 members countries and 182 sites. The study 
enrolled consecutive AF patients presenting to cardiology services, with AF diagnosed within 
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12 months by an established ECG recording technique as primary or secondary diagnosis. 
The enrolment procedures were performed from September 2003 to July 2004. A 1-year 
follow-up observation was originally planned. Details about the study protocol and main 
results have been reported elsewhere[6,10]. 
 
Both the studies shared similar exclusion criteria: age below 18 years old, missing 
electrocardiographic proof of AF, qualifying episode occurred more than 12 months before 
enrolment, only atrial flutter recorded and taking part in an interventional cardiac trial. All 
patients, in both the studies, were enrolled after signing the written informed consent. The 
studies were approved by an institutional review board at every site. Both the studies were 
conducted according to the Declaration of Helsinki. No major differences between the two 
study designs were ascertained, being substantially comparable beyond the number of 
countries included in the surveys. 
 
From the original EORP-AF cohort, 3119 patients were retrieved, while from EHS 5334 
patients were included for the analysis. Case report forms were filled by investigators at each 
enrolling centre, based on patients’ demographics, baseline characteristics and clinical 
history. The two original cohorts have been merged together, constructing an overall study 
cohort of 8453 patients. 
 
2.2 Datasets Merging and Definitions 
Original datasets were similar in main information requested and they overlapped in most of 
the variables considered. Due to the changes in epidemiological definitions, clinical 
management and available drugs over the 10 years between the two registries, several 
adjustments and reclassifications have been made to fully merge the two datasets. as reported 
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in Supplementary Materials (Table S1). All clinical characteristics reported were collected as 
part of patients’ clinical history and obtained from medical interview and/or from clinical 
notes/clinical data archives. 
 
Thromboembolic risk was been defined according both CHADS2 (Congestive Heart Failure, 
Hypertension, Age³65 years, Diabetes Mellitus, Stroke/Transient Ischemic Attack) and 
CHA2DS2-VASc (Congestive Heart Failure, Hypertension, Age³75 years, Diabetes Mellitus, 
Stroke/TIA, Vascular Disease, Age 65-74 years, Sex Category [Female]) scores[11]. 
Thromboembolic risk was categorised according to CHADS2 as 0, 1 and ³2.  Based on 
CHA2DS2-VASc, patients were categorised as “Low Risk” (CHA2DS2-VASc 0 in males and 
1 in females), “Moderate Risk” (male patients with CHA2DS2-VASc 1) and “High Risk” 
(CHA2DS2-VASc ³2). 
 
2.3 Follow-Up Procedures 
Patients from both studies were contacted 1 year after enrolment and the following major 
adverse events were recorded: stroke, transient ischemic attack, peripheral embolism, acute 
coronary syndrome, coronary intervention, any overt coronary artery disease, bleeding 
(intended as any major or clinically relevant bleeding), hospitalizations and cardiovascular 
(CV) and all-cause death. All events were collected according to self-reporting from patient 
and/or relatives and whenever available, from clinical notes/clinical data archives and 
assigned at investigator level. Follow-up checks were performed both as clinical visit(s) 
and/or telephonic interview(s). 
 
2.4 Statistical Analysis 
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Continuous variables are reported as mean±SD or as median and IQR. Between group 
comparisons were made using a non-parametric test (Kruskal-Wallis test). Categorical 
variables were reported as counts and percentages. Between group comparisons were made 
using a chi-square test or Fisher’s exact test (if any expected cell count was less than five).  
 
Pooling data together a possible selection bias should be considered. In order to reduce the 
influence of such selection bias, a PSM procedure was performed to obtain two homogenous 
groups of patients, in terms of baseline characteristics and risk factors, from the historical 
cohort and the current cohort. PSM was compiled according to a selection of pre-specified 
covariates among demographics (age, gender), clinical characteristics (type of AF, systolic 
blood pressure, diastolic blood pressure, body mass index) and risk factors (hypertension, 
hypercholesterolemia, diabetes mellitus, current smoking, no regular exercise). Details about 
the PSM have been reported in Supplementary Methods. 
 
After the PSM procedure, a logistic regression analysis was performed to establish the factors 
significantly associated with AF as the main reason for admission. A list of major clinical 
variables (age, gender, hypertension, diabetes mellitus, chronic heart failure, vascular disease, 
stroke/TIA, previous bleeding event, renal disease, chronic obstructive pulmonary disease) as 
well as the original study of enrolment exposure (EORP-AF vs. EHS) underwent univariate 
analysis. All variables associated with the dependent variable with a p-value <0.10 were 
selected to enter a stepwise regression multivariate analysis. 
 
After PSM, a logistic regression analysis was performed to establish associations between 
original cohort of study of enrolment exposure and 1-year follow-up major adverse events. 
Two multivariate models were performed. In the first, the logistic regression analysis was 
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adjusted for age, gender, type of AF and CHA2DS2-VASc score. In the second model, 
association with the occurrence of major adverse events was adjusted for all the previous 
covariates plus the use of any OAC. 
 
A survival analysis was performed after the PSM procedure. Plots of the Kaplan-Meier 
curves for time to CV death and all-cause death according to original study of enrolment 
exposure (EORP-AF vs. EHS) were performed. The survival distributions were compared 
using the log-rank test. A Cox regression analysis was also performed for the occurrence of 
CV death and all-cause death. A pre-specified list of covariates was selected based on 
biological plausibility (age, gender, type of AF, hypertension, diabetes mellitus, chronic heart 
failure, vascular disease, stroke/transient ischemic attack, use of any OAC) and in addition to 
the original study of enrolment exposure (EORP-AF vs. EHS) underwent univariate analysis. 
The time-to-event analysis was only used for death outcomes, since the exact timing for 
individual major adverse events was not known. All variables found to be associated with the 
dependent variable with a p-value <0.10 were entered into the stepwise regression 
multivariate analysis. All analyses were performed using SAS statistical software version 9.4 
(SAS Institute, Inc., Cary, NC, USA). 
 
3. RESULTS 
 
The merged dataset consisted of 8453 patients (58.5% male) with a median [IQR] age of 69.0 
[60.0-76.2], with 29.9% (2530) aged ³75 years. Most (73.9%, n= 6241) were admitted for 
AF, with paroxysmal AF in 28.2% (n= 2325) (Tables S1-S2, S4-S6). Median [IQR] CHADS2 
score was 2 [1-2], with 52.0% having a CHADS2 score ³2. Median [IQR] CHA2DS2-VASc 
score was 3 [2-4], with CHA2DS2-VASc score ³2 in 77.3% Overall, 2502 patients (30.1%) 
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were prescribed aspirin and 5851 (70.5%) with a OAC. An antiarrhythmic drug (AAD) was 
prescribed in 39.3% (n= 3264). The PSM procedure resulted in a merged population of 5206 
patients (Table 1). 
 
3.1 Baseline Characteristics and Management 
Baseline characteristics were compared between the two registries both before (Table S2) and 
after PSM (Table 1, Panel a). Comparing EORP-AF and EHS, the proportion of elderly 
patients (age ³75 years or ³80 years) were higher in EORP-AF than in EHS both before and 
after PSM. There were no differences in the proportion of females. Patients were more 
frequently admitted for reason other than AF in EORP-AF than EHS (39.8% vs. 18.0%, 
p<0.001). Both before and after PSM, patients in EORP-AF were less symptomatic on 
admission than those enrolled in EHS. 
 
Even after PSM, patients enrolled in EORP-AF were more likely to be diagnosed with 
several concomitant major cardiac and vascular comorbidities (Table 1, Panel a). Also, prior 
bleeding was more commonly reported in EORP-AF than in EHS (p<0.001). Among the non-
cardiovascular comorbidities, after the PSM, EORP-AF patients were more likely to have 
renal disease than EHS patients (p<0.001), and less likely to have chronic obstructive 
pulmonary disease (p=0.014). Catheter ablation was more prevalent in EORP-AF than in 
EHS (p<0.001).  
 
3.2 Factors Associated with AF as Main Reason for Admission  
After univariate analysis (Table S4), age (p<0.001), chronic heart failure (p<0.001), 
hypertension (p=0.042), vascular disease (p<0.001) and renal disease (p<0.001) were 
inversely associated with AF as main reason for admission [Figure S1]. Being part of EORP-
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AF study was inversely associated with AF as main reason for admission (odds ratio [OR]: 
0.34, confidence interval [CI]: 0.29-0.41, p<0.001) [Figure S1]. 
 
3.3 Thromboembolic Risk 
Higher CHADS2 score, expressed both as mean and median (both p<0.001), was found in 
EORP-AF than in EHS cohort after PSM (Table 1, Panel c). Similarly, the CHA2DS2-VASc 
score was higher in EORP-AF patients than EHS patients (both p<0.001 in mean and median 
differences) [Figure S2]. Patients categorized as “high risk” were more prevalent in EORP-
AF than EHS. After the PSM, CHADS2 score ³2 was found in 61.2% in EORP-AF (vs. 
50.7% in EHS, p<0.001), while CHA2DS2-VASc score ³2 was reported for 81.8% in EORP-
AF (vs. 79.3%, p=0.021). 
 
3.4 Antithrombotic Drugs and Pharmacological Treatments 
Use of antithrombotic drugs, as well as the other pharmacological treatments, in EORP-AF 
and EHS were compared after admission/consultation before (Table S6) and after the PSM 
matching (Table 1, Panel d).  
 
The use of antithrombotic drugs increased in EORP-AF patients compared to EHS (95.3% vs. 
92.9%, p<0.001), after PSM. The use of aspirin, as well as any antiplatelet drug, was similar 
between the two cohorts. Use of OAC increased both before and after PSM matching. 
Vitamin K antagonist use was significantly higher in EORP-AF than EHS (72.4% vs. 64.9%, 
p<0.001) and the use of any OAC was even higher (80.4% vs. 64.9%, p<0.001). Concomitant 
use of antiplatelet drugs and OAC was also increased (20.3% vs. 8.2%, p<0.001). In high 
thromboembolic risk patients [Figure 1], the proportion of patients prescribed oral antiplatelet 
drugs only and no antithrombotic therapy were significantly lower in EORP-AF patients than 
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in EHS (both p-values <0.001). The proportion of patients treated with combination 
antiplatelet drug(s) and OAC was significantly higher in EORP-AF compared to EHS [Figure 
1].  
 
3.5 Follow-up Analysis 
Among the overall cohort, 7757 (91.8%) patients were eligible for the 1-year follow-up 
analysis (Table S7), while in the PSM cohort, 4768 (91.6%) were available for analysis 
(Table S8).  
 
In the PSM matched cohort, patients enrolled in EORP-AF had a significant lower rate of 
stroke/TIA (0.9% vs. 3.3%, p<0.001) as well as stroke/TIA/peripheral embolism (1.0% vs. 
3.5%, p<0.001). The rate of coronary artery disease/acute coronary syndrome was 
significantly lower in EORP-AF than EHS (3.7% vs. 5.9%, p<0.001). No difference in rates 
of any bleeding events between the two cohorts was evident. 
 
A higher rate of CV death was reported in EORP-AF study compared to EHS (4.3% vs. 
2.1%, p<0.001). A non-significant trend for higher rate of all-cause death was also evident in 
EORP-AF than in EHS (6.5% vs. 5.3%; p=0.090). The readmission rate for AF was 
significantly lower in EORP-AF than EHS (17.4% vs. 39.0%, p<0.001). Both the rate of 
readmission for other CV reasons (12.1% vs. 20.1%, p<0.001), as well as the rate of 
readmission for non-CV reasons (p<0.001) were significantly lower in EORP-AF cohort. 
 
3.6 Multivariate Regression and Survival Analyses 
A logistic regression analysis was performed to establish the relationship between the study 
exposure (EORP-AF vs. EHS) and major adverse events (Table 2, Panel a). Multivariate 
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model 1, adjusted for age, gender, type of AF and CHA2DS2-VASc score found that patients 
in the EORP-AF study had a lower risk for occurrence of stroke/TIA (p<0.001), 
stroke/TIA/peripheral embolism (p<0.001), coronary artery disease/acute coronary syndrome 
(p=0.001), readmission for AF and for other CV reasons (both p-values <0.001). Conversely, 
the risk of CV death was higher in EORP-AF study than in EHS (p=0.019). The fully 
adjusted model, adding the use of any OAC, confirmed a higher risk for CV death in EORP-
AF (OR: 2.54, 95% CI: 1.20-5.40, p=0.015), while no difference was reported for all-cause 
death. Kaplan-Meier analysis [Figure 2] shows that patients in EORP-AF study had a higher 
risk for CV death (p<0.0001) and all-cause death (p=0.0019) compared to EHS. 
 
Cox regression analysis (Table 2, Panel b) found that patients in EORP-AF were at higher 
risk for CV death (hazard ratio [HR]: 2.71, 95% CI: 1.70-4.33, p<0.001) and all-cause death 
(HR: 1.56, 95% CI: 1.15-2.11, p=0.004). Multivariate analysis shows that patients enrolled in 
EORP-AF had a higher risk for CV death (HR: 1.62, 95% CI: 1.08-2.45, p=0.021) at 1-year 
follow-up, independent of other relevant risk factors (Table 4). Multivariate analysis did not 
show an independent increased risk for all-cause death due to being part of EORP-AF. 
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4. DISCUSSION 
 
This paper provides a unique insight into temporal changes in atrial fibrillation (AF) 
epidemiology in Europe over a decade. First, we found that the proportion of elderly and very 
elderly patients has significantly increased over time, with only 60% of symptomatic patients. 
Second, patients enrolled in EORP-AF had with a higher prevalence of CV comorbidities 
(i.e. previous myocardial infarction, chronic heart failure, cardiomyopathy, peripheral arterial 
disease).  Third, clinical management of AF patients remained mainly unchanged over ten 
years, with a significant increase only for catheter ablation use. Fourth, overall 
thromboembolic risk was increased compared to ten years previously, with a marked increase 
in the use of OAC therapy. Finally, there was a significant decrease in rates of both 
thromboembolic and major CV events, but a significant increase in all-cause and CV 
mortality.  
 
Both AF prevalence and incidence rise according to increasing age, and particularly in 
elderly and very elderly patients[1]. Importantly, increasing age increases morbidity and 
mortality in AF patients[12,13]. A similar analysis of trends in AF patients admitted to 
Medicare beneficiaries in USA, showed that from 1999 to 2013 there was a progressive 
increase in age and proportion of very elderly patients (age ≥85 years)[4]. 
 
Proportionally, various comorbidities were increased among European AF patients. There 
was a significant increase in the prior history of myocardial infarction and coronary 
interventions, as well as in chronic heart failure, valvular disease, cardiomyopathy (regardless 
of type) and peripheral arterial disease, which are relevant for patients’ management. One 
main reason for these strong differences could be related to the increasing age of patients and 
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higher prevalence of of concomitant comobidities.   Furthermore, patients who are more 
clinically complex could have a higher risk of adverse events, as already reported for clinical 
characteristics that could be interpreted as health status markers, such as 
polypharmacy[14,15]. These data also underline how comorbidities have changed over time, 
as well as the relationship between AF and cardiovascular and vascular diseases[16,17]. 
Accordingly, thromboembolic risk profile has significantly increased in European AF 
patients over these ten years.  
 
One of the main findings of our paper is the significant increase in OAC use in the 10 years 
between EHS and EORP-AF. These data confirm previous reports on how worldwide there 
has been a progressive increase in the use of OAC[18,19].  The increase in the use of OAC 
has been driven by increased awareness of AF and stroke, guideline changes and the 
progressive increase in the uptake of non-vitamin K antagonist oral anticoagulants[18,19]. 
Nonetheless, a large proportion of high-risk patients are still treated with single antiplatelet 
therapy (>13%) and more than a quarter of these patients were treated with dual 
antithrombotic therapy (OAC plus antiplatelet drug), although these data could be related to 
the presented changes in clinical history of myocardial infarction and coronary interventions. 
 
In the context of an improved management and increased OAC use over the course of ten 
years European AF patients have less hospital readmissions, both for AF and other CV-
related reasons, and fewer thromboembolic and CV events. Nonetheless, despite various 
cardiovascular prevention drugs were used in the management of AF patients, there was a 
significant increase of CV death that occurred between EHS and EORP-AF registries.  Data 
coming from the US Medicare programme, reported a similar reduction in 30-day 
readmission rate, as well as an increase in the 1-year mortality rate, even if after full 
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adjustment the mortality rate was mostly unchanged[4]. Our data show that even if similar 
evidence was found for all-cause mortality in PSM, European AF patients still do suffer from 
a higher risk for CV death, independently of other risk factors. 
 
The increased risk of death and CV death, even despite OAC use, has been highlighted in 
several previous studies[3,9,13,14].  AF patients may be progressively more clinically 
complex, due to the progressively increasing age and the higher prevalence of major CV 
diseases, partly explaining the increase in CV death. Perhaps the time has come for a change 
on the horizon of clinical management for AF patients. As already highlighted by the 2016 
ESC guidelines, a more integrated approach to AF patient management is needed in order to 
further reduce the risk of major adverse outcomes[1]. Moreover, this approach seems 
justified by recent data showing how an integrated approach leads to a significant reduction 
in all-cause death and CV related hospitalizations, although no difference was noted in terms 
of cerebrovascular events[20]. The use of more integrated approaches to evaluate and treat 
globally AF patients, with a specific focus in managing and treating concomitant conditions, 
has been suggested with the ABC pathway[21].   
 
4.1 Limitations 
The main limitation of our analysis is due to the observational nature of the study. Also, our 
analysis is based on differences between two time-points and not supported by a full time-
dependent analysis. Further, the small number of variables taken to draw the PSM model may 
have left residual confounders, as well as the changes to clinical definitions over time could 
have partially influenced the analysis. As highlighted in Methods section, relevant differences 
exist between the two original studies, in particular related to number of countries, number of 
centres and their distribution.  Notwithstanding the PSM procedure, these differences could 
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still persist and bring an inherited bias that could limit the generalizability of the results. 
Future longitudinal studies could probably verify and better substantiate our hypothesis. 
Moreover, the 1-year follow-up could be considered as a limited observation time to fully see 
differences in mortality events. Finally, we were not able to account for differences in social 
and economic conditions in the time elapsed between the two studies. 
 
5. CONCLUSIONS 
Over a decade, significant temporal changes have been found in AF epidemiology, with 
European AF patients becoming older and more burdened with comorbidities. Relevant 
changes have been also found in patients’ management, with greater OAC usage.  Despite the 
reduction in risk for thromboembolic events, a significant risk of CV-related death still 
persists. Greater efforts are needed to develop more integrated approaches for AF 
management that would impact on a significant reduction in CV mortality.  
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FIGURE LEGENDS 
 
Figure 1: Antithrombotic Drugs Patterns in High-Risk Patients in the Two Cohorts 
Legend: OAC= Oral Anticoagulant. 
 
Figure 2: Kaplan-Meier Curves for Cardiovascular and All-Cause Death 
Legend: EHS= European Heart Survey; EORP-AF= EURObservational Research Program 
Atrial Fibrillation. 
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Table 1: Baseline Characteristics, Clinical Management, Thromboembolic Risk and 
Pharmacological Management after Propensity Score Matching 
 EORP-AF Pilot 
2012-2013 
N=2603 
EHS 
2003-2004 
N=2603 
p Std. 
Diff. 
a) Baseline Characteristics  
Demographics  
Age years, median [IQR] 69.0 [61.0-77.0] 69.7 [61.4-76.4] 0.297 0.04 
Age Classes, n (%) 
<65 years 
65-74 years 
≥75 years 
 
876 (33.7) 
854 (32.8) 
873 (33.5) 
 
891 (34.2) 
918 (35.3) 
794 (30.5) 
0.045 0.07 
Age Classes, n (%) 
<80 years 
≥80 years 
 
2143 (82.3) 
460 (17.7) 
 
2257 (86.7) 
346 (13.3) 
<0.001 0.12 
Gender, n (%) 
Female 
Male 
 
1046 (40.2) 
1557 (59.8) 
 
1084 (41.6) 
1519 (58.4) 
0.284 0.03 
Clinical Characteristics  
Admission Main Reason, n (%) 
AF 
Other than AF 
 
1566 (60.2) 
1037 (39.8) 
 
2144 (82.6) 
453 (17.4) 
<0.001 0.51 
Type of AF, n (%) 
First Detected 
Paroxysmal 
Persistent 
Permanent 
 
802 (30.8) 
689 (26.5) 
665 (25.5) 
447 (17.2) 
 
721 (27.7) 
713 (27.4) 
690 (26.5) 
479 (18.4) 
0.099 0.07 
Symptomatic Status, n (%) 
Previously Symptomatic 
Currently Symptomatic 
Never Symptomatic 
 
604 (23.2) 
1576 (60.5) 
423 (16.3) 
 
324 (12.8) 
1881 (74.3) 
328 (12.9) 
<0.001 0.31 
SBP mmHg, median [IQR] 130 [120-142] 130 [120-145] 0.065 0.03 
DBP mmHg, median [IQR] 80 [70-87] 80 [70-90] 0.060 0.03 
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BMI kg/m2, median [IQR] 27.4 [24.7-30.6] 27.1 [24.6-30.1] 0.039 0.00 
Risk Factors  
Diabetes Mellitus, n (%) 530 (20.4) 514 (19.7) 0.580 0.02 
Hypercholesterolemia, n (%) 1277 (49.1) 1216 (46.7) 0.091 0.05 
Current Smoking, n (%) 295 (11.3) 316 (12.1) 0.366 0.03 
No Regular Exercise, n (%) 1922 (73.8) 1958 (75.2) 0.252 0.03 
Alcohol Excess*, n (%) 190 (7.5) 129 (5.2) <0.001 0.09 
Cardiovascular Comorbidities  
Hypertension, n (%) 1847 (71.0) 1811 (69.6) 0.275 0.03 
CAD, n (%) 832 (36.7) 905 (34.8) 0.170 0.04 
Previous MI, n (%) 374 (16.5) 100 (3.9) <0.001 0.43 
Previous PCI/CABG, n (%) 390 (17.2) 349 (13.4) <0.001 0.10 
Stable Angina, n (%) 320 (14.1) 586 (22.6) <0.001 0.22 
Chronic Heart Failure, n (%) 1216 (49.0) 804 (31.1) <0.001 0.37 
Valvular Disease, n (%) 1593 (64.9) 639 (25.0) <0.001 0.88 
Cardiomyopathy, n (%) 843 (34.2) 277 (10.8) <0.001 0.58 
Dilated Cardiomyopathy, n (%) 281 (11.4) 153 (5.9) <0.001 0.20 
Hypertrophic Cardiomyopathy, n (%) 101 (4.1) 52 (2.0) <0.001 0.12 
Restrictive Cardiomyopathy, n (%) 13 (0.5) 3 (0.1) 0.010 0.07 
Other Cardiomyopathy, n (%) 528 (21.4) 67 (2.6) <0.001 0.60 
Other Cardiac Disease, n (%) 198 (8.2) 240 (9.2) 0.210 0.04 
Previous Stroke/TIA, n (%) 290 (11.2) 260 (10.0) 0.150 0.04 
Any Thromboembolism, n (%) 346 (13.4) 334 (13.0) 0.680 0.01 
PAD, n (%) 291 (11.7) 219 (8.5) <0.001 0.11 
Vascular Disease, n (%) 595 (27.2) 310 (12.1) <0.001 0.39 
Previous Bleeding, n (%) 162 (6.3) 74 (2.9) <0.001 0.16 
Non-Cardiovascular Comorbidities  
COPD, n (%) 297 (11.5) 356 (13.8) 0.014 0.07 
Renal Disease, n (%) 357 (13.8) 168 (6.5) <0.001 0.24 
Thyroid Disease, n (%) 268 (10.7) 245 (10.5) 0.831 0.01 
Malignancy, n (%) 132 (5.2) 148 (5.8) 0.327 0.03 
b) Clinical Management  
Pharmacological Conversion, n (%) 631 (24.4) 662 (25.5) 0.386 0.02 
Electrical Conversion, n (%) 509 (19.8) 511 (19.7) 0.940 0.00 
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Catheter Ablation, n (%) 145 (5.6) 65 (2.5) <0.001 0.16 
Pacemaker Implantation, n (%) 118 (4.5) 119 (4.6) 0.933 0.00 
ICD Implantation, n (%) 16 (0.6) 15 (0.6) 0.862 0.00 
AF Surgery, n (%) 7 (0.3) 2 (0.1) 0.179 0.05 
c) Thromboembolic Risk  
CHADS2, mean (SD) 1.9 (1.3) 1.7 (1.2) <0.001 0.19 
CHADS2, median [IQR] 2 [1-3] 2 [1-2] <0.001 0.19 
CHADS2 Classes, n (%) 
0 
1 
≥2 
 
323 (12.4) 
687 (26.4) 
1593 (61.2) 
 
380 (14.6) 
903 (34.7) 
1320 (50.7) 
<0.001 0.22 
CHA2DS2-VASc, mean (SD) 3.3 (1.8) 2.9 (1.6) <0.001 0.18 
CHA2DS2-VASc, median [IQR] 3 [2-4] 3 [2-4] <0.001 0.18 
CHA2DS2-VASc Classes, n (%) 
Low Risk 
Moderate Risk 
High Risk 
 
215 (8.3) 
259 (10.0) 
2129 (81.8) 
 
219 (8.4) 
321 (12.3) 
2063 (79.3) 
0.021 0.08 
d) Pharmacological Management  
Antithrombotic Therapy  
Aspirin, n (%) 798 (30.7) 805 (31.5) 0.521 0.02 
Any Antiplatelet, n (%) 889 (34.2) 882 (34.6) 0.796 0.01 
Vitamin K Antagonist, n (%) 1879 (72.4) 1653 (64.9) <0.001 0.16 
Any OAC, n (%) 2087 (80.4) 1653 (64.9) <0.001 0.35 
Any Antithrombotic, n (%) 2478 (95.3) 2371 (92.9) <0.001 0.10 
Any Antiplatelet + OAC, n (%) 527 (20.3) 210 (8.2) <0.001 0.35 
Other Antithrombotic, (%) 29 (1.1) 46 (1.8) 0.040 0.06 
Antiarrhythmic Drugs  
Class Ia, n (%) 1 (0.0) 13 (0.5) 0.001 0.09 
Class Ic, n (%) 279 (10.7) 233 (9.1) 0.055 0.05 
Class III, n (%) 665 (25.6) 900 (35.3) <0.001 0.21 
Amiodarone, n (%) 543 (20.9) 714 (28.0) <0.001 0.17 
Any Antiarrhythmic, n (%) 934 (35.9) 1144 (44.8) <0.001 0.18 
Other Medications  
Beta-Blockers, n (%) 1813 (69.8) 1131 (44.3) <0.001 0.53 
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Digoxin, n (%) 507 (19.5) 568 (22.3) 0.015 0.07 
Non-DHP CCB, n (%) 165 (6.3) 214 (8.4) 0.005 0.08 
ACE Inhibitors, n (%) 1131 (43.5) 1303 (51.1) <0.001 0.15 
ARBs, n (%) 566 (21.8) 339 (13.3) <0.001 0.22 
Statins, n (%) 1280 (49.3) 826 (32.4) <0.001 0.35 
Antidiabetic Drugs, n (%) 465 (17.9) 358 (14.0) <0.001 0.11 
Legend: *≥8 units per week; ACE= Angiotensin Converting Enzyme; AF= Atrial 
Fibrillation; ARB= Angiotensin Receptor Blockers; BMI= Body Mass Index; CABG= 
Coronary Artery By-pass Graft; CAD= Coronary Artery Disease; CCB= Calcium-Channel 
Blockers; COPD= Chronic Obstructive Pulmonary Disease; DBP= Diastolic Blood Pressure; 
DHP= Dihydropyridine; EHS= European Heart Survey; EORP-AF= EURObservational 
Research Program Atrial Fibrillation; ICD= Implantable Cardioverter Defibrillator; IQR= 
interquartile feeling; MI= Myocardial Infarction; OAC= Oral Anticoagulant; PAD= 
Peripheral Arterial Disease; PCI= Percutaneous Coronary Intervention; SBP= Systolic Blood 
Pressure; SD= Standard Deviation; TIA= Transient Ischemic Attack.
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Table 2: Multivariate Regression and Survival Analyses for Outcomes at 1-year Follow-Up after Propensity Score Matching 
a) Multivariate Logistic Regression Analyses for EORP-AF Pilot vs. EHS on Outcomes 
 MODEL 1* MODEL 2† 
OR 95% CI p OR 95% CI p 
Stroke/TIA 0.18 0.07-0.44 <0.001 0.18 0.07-0.44 <0.001 
Stroke/TIA/PE 0.21 0.09-0.48 <0.001 0.21 0.09-0.49 <0.001 
CAD/MI 0.55 0.38-0.79 0.001 0.56 0.38-0.83 0.004 
Any Bleeding 0.72 0.33-1.56 0.400 0.63 0.27-1.50 0.300 
CV Death 2.32 1.15-4.68 0.019 2.54 1.20-5.40 0.015 
CV Death - Stroke/TIA - Any Bleeding 0.83 0.57-1.21 0.322 0.84 0.57-1.25 0.388 
CV Death - CAD/MI 0.87 0.64-1.17 0.352 0.88 0.64-1.21 0.431 
All-Cause Death 1.25 0.85-1.85 0.256 1.23 0.82-1.85 0.321 
Readmission for AF 0.34 0.26-0.43 <0.001 0.29 0.22-0.38 <0.001 
Readmission for Other CV Reasons 0.44 0.32-0.61 <0.001 0.44 0.32-0.61 <0.001 
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b) Cox Regression Analyses for Cardiovascular Death and All-Cause Death 
 UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS 
HR 95% CI p HR 95% CI p 
Cardiovascular Death       
Age (per year) 1.06 1.02-1.09 <0.001 1.04 1.02-1.06 <0.001 
Female Gender 1.56 0.83-2.93 0.163 - - - 
Type of AF 
First Detected 
Paroxysmal 
Persistent 
Permanent 
 
- 
0.21 
0.47 
1.04 
 
- 
0.07-0.63 
0.21-1.07 
0.34-3.15 
 
- 
0.006 
0.071 
0.950 
 
- 
0.35 
0.53 
0.62 
 
- 
0.19-0.64 
0.33-0.84 
0.39-0.97 
 
- 
<0.001 
0.007 
0.037 
Hypertension 0.85 0.45-1.62 0.622 - - - 
Diabetes Mellitus 2.46 1.29-4.69 0.006 1.84 1.28-2.65 0.001 
Vascular Disease 4.43 1.95-10.06 <0.001 2.32 1.60-3.36 <0.001 
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Previous Stroke/TIA 2.14 0.87-5.25 0.096 - - - 
Chronic Heart Failure 6.29 2.83-13.96 <0.001 4.11 2.64-6.42 <0.001 
Any OAC 1.17 0.62-2.19 0.631 - - - 
EORP-AF Pilot (vs. EHS) 2.71 1.70-4.33 <0.001 1.62 1.08-2.45 0.021 
All-Cause Death       
Age (per year) 1.09 1.06-1.12 <0.001 1.06 1.05-1.08 <0.001 
Female Gender 1.19 0.77-1.86 0.432 - - - 
Type of AF 
First Detected 
Paroxysmal 
Persistent 
Permanent 
 
- 
0.44 
0.60 
2.70 
 
- 
0.21-0.95 
0.32-1.13 
1.12-6.47 
 
- 
0.037 
0.114 
0.027 
 
- 
0.55 
0.59 
0.81 
 
- 
0.37-0.81 
0.41-0.84 
0.59-1.13 
 
- 
0.002 
0.003 
0.221 
Hypertension 1.09 0.69-1.72 0.726 - - - 
Diabetes Mellitus 2.13 1.30-3.50 0.003 1.61 1.22-2.11 <0.001 
 32 
Vascular disease 2.72 1.59-4.67 <0.001 1.79 1.36-2.34 <0.001 
Previous Stroke/TIA 1.56 0.83-2.93 0.163 - - - 
Chronic Heart Failure 3.48 2.14-5.65 <0.001 2.49 1.88-3.30 <0.001 
Any OAC 0.87 0.55-1.39 0.554 - - - 
EORP-AF Pilot (vs. EHS) 1.56 1.15-2.11 0.004 - - - 
Legend: *Adjusted for age, gender, type of AF, CHA2DS2-VASc; †Adjusted for all previous covariates plus use of any OAC; AF= Atrial 
Fibrillation; CAD= Coronary Artery Disease; CI= Confidence Interval; CV= Cardiovascular; EHS= European Heart Survey; EORP-AF= 
EURObservational Research Program Atrial Fibrillation; HR= Hazard Ratio; MI= Myocardial Infarction; OR= Odds Ratio; OAC= Oral 
Anticoagulant; PE= Peripheral Embolism; TIA= Transient Ischemic Attack.  
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SUPPLEMENTARY METHODS 
Propensity Score Matching 
The propensity score matching (PSM) procedure has been performed in order to get two 
homogenous cohorts to be compared. 
The propensity score (PS) has been estimated according to some pre-specified covariates. 
Four continuous variables (age, body mass index, systolic blood pressure and diastolic blood 
pressure) and seven categorical variables (gender, type of atrial fibrillation [AF], 
hypertension, hypercholesterolemia, diabetes mellitus, current smoking, no regular exercise). 
The score was estimated according to a regression logistic model. Before the model was built 
some preconditions have been verified:  
a. For qualitative variables: Verification of the absence of "Zero cell" in the cross table 
between the outcome and the covariate. If one "zero cell" is observed, some modalities 
have to be merged.  
b. For categorical variable: Verification of the linear link between study exposure and the 
covariate (visual verification, using quartiles of the covariate). If none linear link: switch 
the variable to qualitative variable. 
c. Collinearity study: no collinearity between covariate included in the regression logistic. 
- Spearman coefficient between continuous variables (if coefficient > 0.8: 
collinearity); 
- Chi2 test and phi coefficient if Chi2 test accepted between qualitative variables (if 
phi coefficient > 0.8: collinearity); 
- ANOVA model (p-value) between 1 continuous variable and 1 qualitative 
continuous. 
- If 2 covariates were collinear, only one have been selected. 
 3 
d. Missing value: if more than 20% of observations are missing for one covariate, this 
covariate was not included in the score. 
 
The matching according to the propensity score has been done as following: 
Utilisation of a Greedy Nearest Neighbour matching 1:1 with caliper.  
a. Matching on the logit of the PS; 
b. 1:1 = matching of 1 patient in the Euro Heart Survey (EHS) and 1 patient in the 
EURObservation Research Programme in AF (EORP-AF) database. The logit(PS) of EHS 
must be close to the EORP-AF patient’s logit(PS); 
c. With caliper = caliper is a limit of the closeness/distance between the two logit(PS) in a 
matching pair. This caliper is often compute with the distribution of the PS: 0.2*standard 
deviation of logit(PS). 
For this matching, has been use the “%PSMatch_Multi” SAS Macro (implemented according 
to http://lexjansen.com/nesug/nesug10/ad/ad05.pdf).  
 
The PS matching goal is balance the 11 covariates used in the PS estimation between the two 
groups. 
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Table S1: Differing Variables and Reclassifications Made to Fully Merge the Datasets 
EORP-AF PILOT EHS 
Baseline Characteristics 
Type of AF 
- First Detected 
- Paroxysmal 
- Persistent  
(Obtained merging Persistent with Long-
Standing Persistent from original CRF) 
- Permanent 
Type of AF 
- First Detected 
- Paroxysmal 
- Persistent 
 
 
- Permanent 
Cardiomyopathy 
- Hypertrophic 
- Dilated 
- Restrictive 
- Other 
(Obtained merging Hypertensive and 
Other from original CRF) 
 
Cardiomyopathy 
- Hypertrophic 
- Dilated 
- Restrictive 
- Other 
 (Obtained merging 
Tachycardiomyopathy, Constrictive, 
Congestive and Other from original 
CRF) 
Any Antiplatelet 
- Aspirin 
- Clopidogrel 
- Prasugrel 
- Ticagrelor 
- Ticlopidine 
- Indobufen 
Any Antiplatelet 
- Aspirin 
- Clopidogrel 
- Dipyridamole 
Any OAC 
- Vitamin K Antagonist 
- Dabigatran 
- Rivaroxaban 
- Apixaban 
- Edoxaban 
Any OAC 
- Vitamin K Antagonist 
Class III Antiarrhythmic Drugs Class III Antiarrhythmic Drugs 
 5 
EORP-AF PILOT EHS 
Baseline Characteristics 
- Amiodarone 
- Dronedarone 
- Sotalol 
- Amiodarone 
- Sotalol 
1-y Follow-Up Outcomes 
CAD/ACS 
- ACS 
- Coronary Intervention 
- Overt CAD 
CAD/ACS 
- New CAD 
- CAD Worsening 
Legend: ACS= Acute Coronary Syndrome; AF= Atrial Fibrillation; CAD= Coronary Artery 
Disease; CRF= Case Report Form; EHS= European Heart Survey; EORP-AF= 
EURObservational Research Program Atrial Fibrillation; OAC= Oral Anticoagulant. 
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Table S2: Baseline Characteristics According Original Cohort before Propensity Score 1 
Matching 2 
 Not Propensity Score Matching Adjusted 
Whole Cohort 
N=8453 
EORP-AF Pilot 
N=3119 
EHS 
N=5334 
p 
Demographics 
Age years, median [IQR] 
Missing 
69.0 [60.0-76.2] 
5 
69.0 [62.0-77.0] 
0 
68.3 [59.0-75.8] 
5 
<0.001 
Age Classes, n (%) 
<65 years 
65-74 years 
≥75 years 
Missing 
 
3160 (37.4) 
2758 (32.6) 
2530 (29.9) 
5 
 
1030 (33.0) 
1038 (33.3) 
1051 (33.7) 
0 
 
2130 (40.0) 
1720 (32.3) 
1479 (27.8) 
5 
<0.001 
Age Classes, n (%) 
<80 years 
≥80 years 
Missing 
 
7230 (85.6) 
1218 (14.4) 
5 
 
2565 (82.2) 
554 (17.8) 
0 
 
4665 (87.5) 
664 (12.5) 
5 
<0.001 
Gender, n (%) 
Female 
Male 
 
3510 (41.5) 
4943 (58.5) 
 
1260 (40.4) 
1859 (59.6) 
 
2250 (42.2) 
3084 (57.8) 
0.108 
Clinical Characteristics 
Admission Main Reason, n (%) 
AF 
Other than AF 
Missing 
 
6241 (73.9) 
2202 (26.1) 
10 
 
1877 (60.2) 
1242 (39.8) 
0 
 
4364 (82.0) 
960 (18.0) 
10 
<0.001 
Type of AF, n (%) 
First Detected 
Paroxysmal 
Persistent 
Permanent 
Missing 
 
1901 (23.0) 
2325 (28.2) 
1960 (23.7) 
2067 (25.0) 
200 
 
923 (30.3) 
808 (26.5) 
792 (26.0) 
526 (17.3) 
70 
 
978 (18.8) 
1517 (29.2) 
1168 (22.4) 
1541 (29.6) 
130 
<0.001 
Symptomatic Status, n (%) 
Previously Symptomatic 
Currently Symptomatic 
Never Symptomatic 
Missing 
 
1510 (18.3) 
5556 (67.3) 
1184 (14.4) 
203 
 
717 (23.0) 
1882 (60.3) 
520 (16.7) 
0 
 
793 (15.5) 
3674 (71.6) 
664 (12.9) 
203 
<0.001 
SBP mmHg, median [IQR] 
Missing 
130 [120-150] 
74 
130 [120-142] 
0 
133 [120-150] 
74 
<0.001 
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DBP mmHg, median [IQR] 
Missing 
80 [70-90] 
76 
80 [70-87] 
2 
80 [70-90] 
74 
<0.001 
BMI kg/m2, median [IQR] 
Missing 
27.1 [24.6-30.2] 
535 
27.4 [24.7-30.7] 
122 
27.0 [24.5-30.1] 
413 
<0.001 
Risk Factors 
Diabetes Mellitus, n (%) 
Missing 
1601 (19.0) 
22 
638 (20.6) 
18 
963 (18.1) 
4 
0.005 
Hypercholesterolemia, n (%) 
Missing 
3335 (40.2) 
156 
1474 (48.4) 
73 
1861 (35.4) 
83 
<0.001 
Current Smoking, n (%) 
Missing 
989 (11.9) 
176 
337 (11.1) 
93 
652 (12.4) 
83 
0.084 
No Regular Exercise, n (%) 
Missing 
6230 (78.5) 
519 
2134 (74.0) 
237 
4096 (81.1) 
282 
<0.001 
Alcohol Excess*, n (%) 
Missing 
498 (6.4) 
713 
226 (7.8) 
214 
272 (5.6) 
499 
<0.001 
Cardiovascular Comorbidities 
Hypertension, n (%) 
Missing 
5558 (65.9) 
22 
2194 (70.7) 
16 
3364 (63.1) 
6 
<0.001 
CAD, n (%) 
Missing 
2607 (32.5) 
434 
977 (36.3) 
431 
1630 (30.6) 
3 
<0.001 
Previous MI, n (%) 
Missing 
603 (7.5) 
448 
439 (16.3) 
431 
164 (3.1) 
17 
<0.001 
Previous PCI/CABG, n (%) 
Missing 
1071 (13.4) 
454 
459 (17.1) 
431 
612 (11.5) 
23 
<0.001 
Stable Angina, n (%) 
Missing 
1393 (17.4) 
469 
365 (13.6) 
431 
1028 (19.4) 
38 
<0.001 
Chronic Heart Failure, n (%) 
Missing 
3060 (37.0) 
187 
1411 (47.5) 
147 
1649 (31.1) 
40 
<0.001 
Valvular Disease, n (%) 
Missing 
3211 (39.3) 
273 
1860 (63.4) 
186 
1351 (25.7) 
87 
<0.001 
Cardiomyopathy, n (%) 
Missing 
1586 (19.3) 
227 
999 (33.8) 
167 
587 (11.1) 
60 
<0.001 
Dilated Cardiomyopathy, n (%) 
Missing 
661 (8.0) 
224 
340 (11.5) 
164 
321 (6.1) 
60 
<0.001 
Hypertrophic Cardiomyopathy, n 
(%) 
Missing 
 
221 (2.7) 
221 
 
115 (3.9) 
161 
 
106 (2.0) 
60 
<0.001 
Restrictive Cardiomyopathy,  
n (%) 
 
22 (0.3) 
 
15 (0.5) 
 
7 (0.1) 
0.002 
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Missing 217 157 60 
Other Cardiomyopathy, n (%) 
Missing 
775 (9.4) 
231 
626 (21.2) 
171 
149 (2.8) 
60 
<0.001 
Other Cardiac Disease, n (%) 
Missing 
695 (8.5) 
235 
239 (8.3) 
235 
456 (8.5) 
0 
0.684 
Previous Stroke/TIA, n (%) 
Missing 
872 (10.3) 
25 
339 (11.0) 
24 
533 (10.0) 
1 
0.164 
Any Thromboembolism, n (%) 
Missing 
1060 (12.7) 
84 
405 (13.1) 
24 
655 (12.4) 
60 
0.376 
PAD, n (%) 
Missing 
738 (9.0) 
242 
328 (11.0) 
144 
410 (7.8) 
98 
<0.001 
Vascular Disease, n (%) 
Missing 
1248 (15.9) 
623 
692 (26.6) 
516 
556 (10.6) 
107 
<0.001 
Previous Bleeding, n (%) 
Missing 
358 (4.3) 
51 
181 (5.8) 
24 
177 (3.3) 
27 
<0.001 
Non-Cardiovascular Comorbidities 
COPD, n (%) 
Missing 
1052 (12.6) 
77 
339 (11.0) 
33 
713 (13.5) 
44 
<0.001 
Renal Disease, n (%) 
Missing 
717 (8.5) 
35 
408 (13.1) 
12 
309 (5.8) 
23 
<0.001 
Thyroid Disease, n (%) 
Missing 
815 (10.4) 
649 
305 (10.2) 
122 
510 (10.6) 
527 
0.543 
Malignancy, n (%) 
Missing 
448 (5.4) 
168 
163 (5.4) 
74 
285 (5.4) 
94 
0.868 
Legend: AF= Atrial Fibrillation; BMI= Body Mass Index; CABG= Coronary Artery By-pass 1 
Graft; CAD= Coronary Artery Disease; COPD= Chronic Obstructive Pulmonary Disease; 2 
DBP= Diastolic Blood Pressure; EHS= European Heart Survey; EORP-AF= 3 
EURObservational Research Program Atrial Fibrillation; IQR= interquartile feeling; MI= 4 
Myocardial Infarction; PAD= Peripheral Arterial Disease; PCI= Percutaneous Coronary 5 
Intervention; SBP= Systolic Blood Pressure; TIA= Transient Ischemic Attack; *≥8 units per 6 
week. 7 
  8 
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Table S3: Differences in Atrial Fibrillation Clinical Management before Propensity Score 1 
Matching 2 
 
Not Propensity Score Matching Adjusted 
Whole Cohort 
N=8453 
EORP-AF Pilot 
N=3119 
EHS 
N=5334 
p 
Pharmacological Conversion, n (%) 
Missing 
 
1889 (22.5) 
46 
 
750 (24.3) 
34 
 
1139 (21.4) 
12 
0.002 
Electrical Conversion, n (%) 
Missing 
1532 (18.2) 
52 
612 (19.9) 
39 
920 (17.3) 
13 
0.003 
Catheter Ablation, n (%) 
Missing 
320 (3.8) 
23 
186 (6.0) 
10 
134 (2.5) 
13 
<0.001 
Pacemaker Implantation, n (%) 
Missing 
338 (4.0) 
23 
134 (4.3) 
4 
204 (3.8) 
19 
0.295 
ICD Implantation, n (%) 
Missing 
48 (0.6) 
24 
21 (0.7) 
7 
27 (0.5) 
17 
0.325 
AF Surgery, n (%) 
Missing 
17 (0.2) 
23 
9 (0.3) 
6 
8 (0.2) 
17 
0.171 
Legend: AF= Atrial Fibrillation; EHS= European Heart Survey; EORP-AF= 3 
EURObservational Research Program Atrial Fibrillation; ICD= Implantable Cardioverter 4 
Defibrillator. 5 
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Table S4: Univariate Logistic Analysis for Atrial Fibrillation as Reason for Admission 1 
 OR 95% CI p 
Age (per year) 0.96 0.95-0.97 <0.001 
Chronic Heart Failure 0.25 0.20-0.31 <0.001 
Hypertension 0.74 0.61-0.89 0.002 
Diabetes Mellitus 0.62 0.50-0.76 <0.001 
Stroke/TIA 0.63 0.48-0.83 0.001 
Vascular Disease 0.21 0.16-0.27 <0.001 
Female Gender 0.92 0.77-1.09 0.315 
Previous Bleeding Event 0.35 0.23-0.53 <0.001 
Renal Disease 0.20 0.15-0.28 <0.001 
COPD 0.63 0.50-0.80 <0.001 
EORP-AF Pilot (vs. EHS) 0.31 0.27-0.36 <0.001 
Legend: CI= Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease; EHS= 2 
European Heart Survey; EORP-AF= EURObservational Research Program Atrial 3 
Fibrillation; OR= Odds Ratio; TIA= Transient Ischemic Attack. 4 
 5 
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Table S5: Thromboembolic Risk Patterns before Propensity Score Matching 1 
 
Not Propensity Score Matching Adjusted 
Whole Cohort 
N=8453 
EORP-AF Pilot 
N=3119 
EHS 
N=5334 
p 
CHADS2, mean (SD) 1.7 (1.3) 1.9 (1.3) 1.6 (1.2) <0.001 
CHADS2, median [IQR] 2 [1-2] 2 [1-3] 1 [1-2] <0.001 
CHADS2 Classes, n (%) 
0 
1 
≥2 
 
1390 (16.4) 
2671 (31.6) 
4392 (52.0) 
 
392 (12.6) 
846 (27.1) 
1881 (60.3) 
 
998 (18.7) 
1825 (34.2) 
2511 (47.1) 
<0.001 
CHA2DS2-VASc, mean (SD) 2.9 (1.7) 3.2 (1.8) 2.8 (1.7) <0.001 
CHA2DS2-VASc, median [IQR] 3 [2-4] 3 [2-4] 3 [1-4] <0.001 
CHA2DS2-VASc Classes, n (%) 
Low Risk 
Moderate Risk 
High Risk 
 
912 (10.8) 
1005 (11.9) 
6536 (77.3) 
 
251 (8.0) 
320 (10.3) 
2548 (81.7) 
 
661 (12.4) 
685 (12.8) 
3988 (74.8) 
<0.001 
Legend: EHS= European Heart Survey; EORP-AF= EURObservational Research Program 2 
Atrial Fibrillation; IQR= Interquartile Range; SD= Standard Deviation. 3 
  4 
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Table S6: Pharmacological Treatments after Admission/Consultation before Propensity 1 
Score Matching 2 
 
Not Propensity Score Matching Adjusted 
Whole Cohort 
N=8453 
EORP-AF Pilot 
N=3119 
EHS 
N=5334 
p 
Antithrombotic Therapy     
Aspirin, n (%) 
Missing 
2502 (30.1) 
139 
957 (30.8) 
7 
1545 (29.7) 
132 
0.312 
Any Antiplatelet, n (%) 
Missing 
2747 (33.0) 
139 
1065 (34.2) 
7 
1682 (32.3) 
132 
0.076 
Vitamin K Antagonist, n (%) 
Missing 
5592 (67.3) 
150 
2228 (71.6) 
9 
3364 (64.8) 
141 
<0.001 
Any OAC, n (%) 
Missing 
5851 (70.5) 
151 
2487 (80.0) 
10 
3364 (64.8) 
141 
<0.001 
Any Antithrombotic, n (%) 
Missing 
7726 (92.9) 
138 
2964 (95.2) 
6 
4762 (91.5) 
132 
<0.001 
Any Antiplatelet + OAC, n (%) 
Missing 
1005 (12.1) 
151 
625 (20.1) 
10 
380 (7.3) 
141 
<0.001 
Other Antithrombotic, (%) 
Missing 
132 (1.6) 
139 
36 (1.2) 
7 
96 (1.8) 
132 
0.015 
Antiarrhythmic Drugs     
Class Ia, n (%) 
Missing 
21 (0.3) 
138 
1 (0.0) 
6 
20 (0.4) 
132 
0.002 
Class Ic, n (%) 
Missing 
813 (9.8) 
138 
317 (10.2) 
6 
496 (9.5) 
132 
0.335 
Class III, n (%) 
Missing 
2424 (29.2) 
139 
804 (25.8) 
7 
1620 (31.1) 
132 
<0.001 
Amiodarone, n (%) 
Missing 
1946 (23.4) 
138 
663 (21.3) 
6 
1283 (24.7) 
132 
<0.001 
Any Antiarrhythmic, n (%) 
Missing 
3264 (39.3) 
139 
1111 (35.7) 
7 
2153 (41.4) 
132 
<0.001 
Other Medications     
Beta-Blockers, n (%) 
Missing 
4425 (53.2) 
142 
2159 (69.4) 
10 
2266 (43.6) 
132 
<0.001 
Digoxin, n (%) 
Missing 
2032 (24.4) 
139 
613 (19.7) 
7 
1419 (27.3) 
132 
<0.001 
Non-DHP CCB, n (%) 
Missing 
668 (8.0) 
140 
190 (6.1) 
8 
478 (9.2) 
132 
<0.001 
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ACE Inhibitors, n (%) 
Missing 
3909 (47.0) 
141 
1344 (43.2) 
9 
2565 (49.3) 
132 
<0.001 
ARBs, n (%) 
Missing 
1349 (16.2) 
140 
677 (21.8) 
8 
672 (12.9) 
132 
<0.001 
Statins, n (%) 
Missing 
2847 (34.3) 
144 
1532 (49.3) 
12 
1315 (25.3) 
132 
<0.001 
Antidiabetic Drugs, n (%) 
Missing 
1266 (15.2) 
138 
557 (17.9) 
6 
709 (13.6) 
132 
<0.001 
Legend: ACE= Angiotensin Converting Enzyme; ARB= Angiotensin Receptor Blockers; 1 
CCB= Calcium-Channel Blockers; DHP= Dihydropyridine; EHS= European Heart Survey; 2 
EORP-AF= EURObservational Research Program Atrial Fibrillation; OAC= Oral 3 
Anticoagulant. 4 
 5 
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Table S7: Outcomes at 1-year Follow-Up before Propensity Score Matching 1 
  
Not Propensity Score Matching Adjusted 
Whole Cohort 
N=7757 
EORP-AF Pilot 
N=2785 
EHS 
N=4972 
p 
Major Adverse Events     
Stroke/TIA, n (%) 154 (2.4) 22 (1.0) 132 (3.2) <0.001 
Stroke/TIA/PE, n (%) 170 (2.7) 25 (1.1) 145 (3.6) <0.001 
CAD/ACS, n (%) 308 (4.7) 85 (3.7) 223 (5.3) 0.003 
Any Bleeding, n (%) 94 (1.4) 25 (1.1) 69 (1.6) 0.071 
CV Death, n (%) 201 (3.0) 107 (4.1) 94 (2.3) <0.001 
CV Death - Stroke/TIA - Any 
Bleeding, n (%) 
423 (6.6) 153 (6.5) 270 (6.6) 0.802 
CV Death - CAD/ACS, n (%) 494 (7.6) 192 (8.0) 302 (7.4) 0.434 
All-Cause Death, n (%) 407 (5.9) 167 (6.3) 240 (5.7) 0.289 
Readmissions     
Readmission for AF, n (%) 1375 (28.2) 411 (18.0) 964 (37.1) <0.001 
Readmission for Other CV 
Reasons, n (%) 
776 (15.7) 271 (11.7) 505 (19.2) <0.001 
Readmission for Non-CV Reasons, 
n (%) 
756 (14.8) 288 (12.5) 468 (16.7) <0.001 
Legend: AF= Atrial Fibrillation; ACS= Acute Coronary Syndrome; CAD= Coronary Artery 2 
Disease; CV= Cardiovascular; EHS= European Heart Survey; EORP-AF= 3 
EURObservational Research Program Atrial Fibrillation; PE= Peripheral Embolism; TIA= 4 
Transient Ischemic Attack.  5 
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Table S8: Outcomes at 1-year Follow-Up after Propensity Score Matching 1 
 EORP-AF Pilot 
N=2335 
EHS 
N=2433 
p Std. 
Diff. 
Major Adverse Events  
Stroke/TIA, n (%) 17 (0.9) 67 (3.3) <0.001 0.17 
Stroke/TIA/PE, n (%) 19 (1.0) 70 (3.5) <0.001 0.17 
CAD/ACS, n (%) 72 (3.7) 123 (5.9) <0.001 0.11 
Any Bleeding, n (%) 23 (1.2) 36 (1.7) 0.134 0.05 
CV Death, n (%) 93 (4.3) 41 (2.1) <0.001 0.13 
CV Death - Stroke/TIA - Any Bleeding, n (%) 132 (6.5) 131 (6.5) 0.982 0.00 
CV Death - CAD/ACS, n (%) 165 (8.1) 155 (7.7) 0.707 0.01 
All-Cause Death, n (%) 146 (6.5) 110 (5.3) 0.090 0.05 
Readmissions  
Readmission for AF, n (%) 337 (17.4) 479 (39.0) <0.001 0.50 
Readmission for Other CV Reasons, n (%) 237 (12.1) 245 (20.1) <0.001 0.22 
Readmission for Non-CV Reasons, n (%) 240 (12.2) 240 (18.3) <0.001 0.17 
Legend: AF= Atrial Fibrillation; ACS= Acute Coronary Syndrome; CAD= Coronary Artery 2 
Disease; CV= Cardiovascular; EHS= European Heart Survey; EORP-AF= 3 
EURObservational Research Program Atrial Fibrillation; PE= Peripheral Embolism; TIA= 4 
Transient Ischemic Attack5 
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Figure S1: Multivariate Logistic Analysis for AF as Main Reason for Admission 
 
Legend: CI= Confidence Interval; EHS= European Heart Survey; EORP-AF= EURObservational Research Program Atrial Fibrillation; OR= 
Odds Ratio.  
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Figure S2: Distribution of CHADS2 and CHA2DS2-VASc Risk Scores between the Two Cohorts 
 
Legend: CI= Confidence Interval; EHS= European Heart Survey; EORP-AF= EURObservational Research Program Atrial Fibrillation; OR= 
Odds Ratio.
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Appendix 
EURObservational Research Programme AF Pilot Registry Committees and 
Investigators 
 
Executive committee: Gregory Y.H. Lip, Luigi Tavazzi, Aldo P. Maggioni, Harry JGM 
Crijns, Paulus Kirchhof and Panos Vardas.  
Steering Committee (National Coordinators): Gheorghe-Andrei Dan, Dan Atar, 
Emmanuel Simantirakis, Massimo Santini, Zbigniew Kalarus, Lars Hvilsted Rasmussen, 
Mario Martins Oliveira, and Georges Mairesse. 
Investigators: BELGIUM Bastogne: M. Raepers, Z. el Husseini; Hasselt: D. Dilling-Boer, J. 
Schurmans, J. Vijgen, P. Koopman; Wilrijk: W. Huybrechts; Yvoir: F. Dormal, D. 
Blommaert, O. Deceuninck, O. Xhaet; DENMARK Aalborg: C. Fragtrup Hellum, B. 
Mortensen, B. Ginnerup Sorensen, A. M. Joensen, L. H. Rasmussen; Copenhagen: A. 
Karlsdottir, S. Pehrson; Esbjerg: J. Hummelshoj, A-M. Svenningsen, L. Tanggaard, 
P.Wiggers, A. Nygaard; Hjorring: A. Jonstrup, J. Petersen; Silkeborg: A. Odgaard, M. 
Mortensen, L. Frost; Viborg: D. Svenstrup Møller, H.M. Søndergaard, P. D. Christensen; 
GREECE Athens: S. Xydonas, L. Lioni; Chios: M. Dimopoulou, G. Georgiopoulos, E. 
Papatheodorou, P. Boutas, A. Kartalis; Heraklion: P. Vardas, H. Nakou, E. Kanoupakis, E. 
Simantirakis; Thessaloniki: D. Tahmatzidis, I. Styliadis, V. Vassilikos; Thessaloniki: K. 
Koskinas, N. Fragakis; Thessaloniki: K. Polymeropoulos, G. Maligos; ITALY Bologna: C. 
Martignani, I. Diemberger, G. Boriani, J. Frisoni, M. Biffi, M. Ziacchi, P. Cimaglia, E. 
Fantecchi; Firenze: S. Boni, D. Gabbai, N. Marchionni, S. Fumagalli; Trieste: M. Bobbo, F. 
Ramani, G. Sinagra, L. Vitali-Serdoz, A. Nordio, A. Porto, M. Zecchin, C. Di Nora; 
Palermo: S. Novo, F. P. Guarneri, F Macaione; NORWAY Haugesund: R. Rød, R.M.O. 
Stødle; Lorenskog: M.O. Pervez, P. Smith, M. Buvarp; Nesttun: P.K. Rønnevik; Oslo: A. 
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Vold, J. Fuglestved, D. Atar; Skedsmokorset: E. Stenshjemmet, K. Risberg; POLAND 
Cieszyn: A. Sokal, A. Kubicius, E. Prochniewicz, K. Pokrywa; Gorzów: R. Rzeuski, A. 
Weryszko; Katowice: M. Haberka, Z. Gasior, A. Slowikowski; Kielce: M. Janion, M. 
Kołodziej, A. Janion-Sadowska; Lodz: J. Drożdż, M. Stasiak, P. Jakubowski, T. Ciurus; 
Lodz: M. Pawlak, M. Nowakowska, K. Wiklo, M. Kurpesa; Nysa: A. Olejnik, J. Miarka; 
Radlin: W. Streb;Warszawa: L. Zielinski, M. Dluzniewski, M. Tomaszewska-Kiecana; 
Warszawa: G. Opolski, M. Budnik, M. Kiliszek; Warszawa: J. Gorska, A. Mamcarz, D. 
Sliz, K. Makowiecki; Wroclaw: A. Fuglewicz, M. Drozd, M. Garncarek; Zabrze: A. 
Musialik-Lydka, E. Markowicz- Pawlus, G. Kaźmierczak; Zabrze: A. Leopold-Jadczyk, M. 
Koziel, Z. Kalarus; PORTUGAL Almada: S. Sobral, H. Pereira, L. Brandao Alves, L. 
Ribeiro, R. Miranda, S. Almeida; Amadora: F. Madeira, M. Faustino, R. Oliveira, V. Gil; 
Braga: C. Braga, J. Martins, S. Rocha, S. Magalhaes, V. Ramos; Carnaxide: R. Bernardo, F. 
Costa, F. Morgado, P. Galvao Santos, N. Almeida, P. Adragao, P. Carmo; Coimbra: G. 
Mariano Pego, J. Ferreira, L. Elvas, M. Ventura, N. António, R. Ferreira; Evora: A.F. 
Damasio, A.R. Santos, B. Piçarra, D. Neves; Faro: I. De Jesus, J. Amado, P. Sousa, R. 
Candeias; Guimaraes: A. Lourenco, A. Pereira, F. Canário-Almeida, M. Fernandes, F. 
Ferreira, I. Machado, I. Quelhas, J. Guardado, V. Pereira; Lisboa: D. Cavaco, N. Almeida, P. 
Adragao, P. Carmo; Lisboa: A. Lousinha, B. Valente, N. Silva, P. Cunha, R. Pimenta, S. 
Santos, M. Martins Oliveira; Lisboa: S. Vicente, A. Bernardes, A. Nunes Diogo, E. 
Rodrigues, J.M. Frazao Rodrigues de Sousa, L. Carpinteiro, M. Satendra, N. Cortez Dias, S. 
Neto; Vila Nova de Gaia: V. Gama Ribeiro, H. Gonçalves, J. Primo, L. Adao, M. Oliveira; 
Viseu: A. Costa, A. Delgado, B. Marmelo, D. Moreira, J. Santos, L. Santos, B.Rodrigues; 
ROMANIA Arad: A. Pop Moldovan, D. Darabantiu; Baia Mare: B. Todea, C. Pop, D. Dicu, 
D. Filip, D. Mercea, G. Kozma, M. Schiopu; Brasov: G. Catanescu, C. Popescu, E. Bobescu, 
A. Gabor; Bucharest: A. Buzea, A. Dan, I. Daha, N. Asan, R. Popescu, G-A. Dan; 
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Bucharest: D. Bartos, E. Badila, E. Tintea, C. Grigore, A.M. Daraban; Bucharest: A. 
Sandulescu, A. Carp, D. Gherasim, I.M. Stoian; Bucharest: M.M. Baluta; Bucharest: M.M. 
Vintila; Oradea: M.I. Popescu, O. Tica; Timisoara: L. Petrescu, N. Alina-Ramona, R. Dan; 
Timisoara: D.C. Cozma, C. Tutuianu, M. Mangea, E. Goanta; THE NETHERLANDS 
Enschede: J. M. Van Opstal, R. van Rennes; Groningen: B.A. Mulder; Hengelo: S. A. M. 
Said; Leeuwarden: R. J. Folkeringa; Maastricht: S. Philippens, H.J.G.M. Crijns, Y. Blaauw, 
I. Aksoy, M. Pluymen, R. Driessen, I. Limantoro, T. Lankveld, M. Mafi Rad, J. Hendriks; 
Venlo:W. H. van Unen, J. Meeder. 
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Euro Heart Survey AF registry Committees and Investigators 
 
Atrial Fibrillation Expert Committee and Consultants: Harry Crijns (Survey Chairman), 
The Netherlands; Robby Nieuwlaat (research fellow), The Netherlands; Dieter Andresen, 
Germany; A. John Camm, UK; Alessandro Capucci, Italy; Wynn Davies, UK; Samuel Le´vy, 
France; Bertil Olsson, Sweden; Etienne Aliot, France; Günter Breithardt, Germany; Stuart 
Cobbe, UK; Jean-Yves Le Heuzey, France; Massimo Santini, Italy; Panos Vardas, Greece. 
Euro Heart Survey Team (European Heart House, France): Malika Manini, Operations 
Manager; Claire Bramley, Data Monitor; Valérie Laforest, Data Monitor; Charles Taylor, 
Database Administrator; Susan Del Gaiso, Administrator. 
Main Investigator Centre (Maastricht, The Netherlands): Harry Crijns (Survey 
Chairman), Robby Nieuwlaat (Research Coordinator). 
National Coordinators: Austria, Kurt Huber; Belgium, Guy De Backer; Bulgaria, Vera 
Sirakova; Czech Republic, Roman Cerbak; Denmark, Per Thayssen; Finland, Seppo Lehto; 
France, Jean-Jacques Blanc, François Delahaye; Georgia, Bondo Kobulia; Germany, Uwe 
Zeymer; Greece, Dennis Cokkinos; Hungary, Kristof Karlocai; Ireland, Ian Graham, Emer 
Shelley; Israel, Shlomo Behar; Italy, Aldo Maggioni; Lithuania, Virginija Grabauskiene; The 
Netherlands, Jaap Deckers; Norway, Inger Asmussen; Poland, Janina Stepinska; Portugal, 
Lino Gonc¸alves; Russia, Vyacheslav Mareev; Serbia and Montenegro, Zorana Vasiljevic; 
Slovakia, Igor Riecansky; Slovenia, Miran F. Kenda; Spain, Angeles Alonso, José Luis 
Lopez-Sendon; Sweden, Annika Rosengren; Switzerland, Peter Buser; Turkey, Tugrul Okay; 
Ukraine, Oleg Sychov; UK, Kevin Fox, Peter Schofield. 
There was no national coordinator in the participating countries which are not mentioned in 
the above list. 
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Euro Heart Survey Board Committee (2000–2004): Maarten Simoons (Chairman), The 
Netherlands, David Wood (past-chairman), United Kingdom; Angeles Alonso, Spain; Alex 
Battler, Israel; Shlomo Behar, Israel; Eric Boersma, The Netherlands; Harry Crijns, The 
Netherlands; Kim Fox, UK; Michel Komajda, France; Malika Manini, France; Keith 
McGregor, France; Barbara Mulder, The Netherlands; Sylvia Priori, Italy; Lars Ryde´n, 
Sweden; Luigi Tavazzi, Italy; Alec Vahanian, France; Panos Vardas, Greece; William Wijns, 
Belgium; Uwe Zeymer, Germany. 
Industry sponsors: main sponsor: AstraZeneca; major sponsor: Sanofi-Aventis; sponsor: 
Eucomed. 
List of Institutions: Austrian Heart Foundation, Austrian Society of Cardiology, French 
Federation of Cardiology, Hellenic Cardiological Society, Netherlands Heart Foundation, 
Portuguese Society of Cardiology, Spanish Cardiac Society, Swedish Heart and Lung 
Foundation and individual centres. 
Participating Centres, Investigators, and Data Collection Officers: Armenia: S.V. 
Grigoryan, I. Apetyan, S. Aroyan, L. Azarapetyan; Austria: Anahit Anvari, Michael 
Gottsauner-Wolf, Stefan Pfaffenberger, Kurt Huber, Kadriye Aydinkoc, Karim Kalla, 
Martina Penka, Heinz Drexel, Peter Langer; Belgium: Luc A. Pierard, Victor Legrand, 
Dominique Blommaert, E. Schroeder, Isabelle Mancini, William Wijns, P. Geelen, P. 
Brugada, Marc De Zutter, Christiaan Vrints, Marc Vercammen, Marielle Morissens; 
Bulgaria: Borislav Boyanov Borisov, Valentin Asenov Petrov, Maria Marinova 
Alexandrova, Assen Rachev Goudev, Vera Sirakova, Yavor Peychev, Vassil Stoyanovsky, 
Evgeni Stoynev; Croatia: Stjepan Kranjcevic; Cyprus: Joseph Moutiris, Marios Ioannides; 
Switzerland: Dominique Evequoz; Czech Republic: Jaroslava Spacilova, Roman Cerbak, 
Miroslav Novak, Martin Eisenberger, Jolana Mullerova, Josef Kautzner, Lucie 
Riedlbauchova, Jan Petru`, Milos Taborsky; Denmark: Per Thayssen, Helle Cappelen; 
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Egypt: Yasser A. Sharaf, B.S.S. Ibrahim, Khalid Tammam, Aly Saad, Helmy Elghawaby, 
Hamed Zaky Sherif, Heba Farouk; Germany: D. Andresen, Arlett Mielke, Gunter Breithardt, 
Markus Engelen, Paulus Kirchhof, Pia Zimmermann; Spain: F. Fernandez Aviles, Jeronimo 
Rubio, F. Malpartida, M. Corona, Luis Tercedor Sanchez, Jose Miguel Lozano Herrera, 
Aurelio Quesada, Antonio J. Munoz Garcia, Carlos Sanchez Gonzalez, M. Soledad Alcasena 
Juango, Jesus Berjon-Reyero, Josep M. Alegret, J.M. Cruz Fernandez, Cesar Carrascosa 
Rosillo, Antonio Fernandez Romero, Miguel Gonzalez Lara, José L. Lopez Sendon, José 
Juan Gomez de Diego, Luis Sosa Martin, Maria Irurita, Norbero Herrera Guttierez, Juan 
Ramon Siles Rubio, Isabel Antorrena, Alicia Bautista Paves, Antonio Salvador, Maria 
Dolores Orriach, A. Alonso Garcia, Francisco Epelde, Vicente Bertomeu Martinez, Antonio 
Berruezo Sanchez, Carlos Pinero Galvez, Rafael Fernandez Rivero, Antonio Hernandez 
Madrid, Gonzalo Baron-Esquivias, Rafael Peinado, Jose´ Antonio Gomez Guindal, Tomas 
Ripoll Vera, Emilio Luengo Fernandez, Ricardo Gayan, Javier Garcia, Andres Bodegas, 
Jesus Toril Lopez, Julio Martinez Florez, Cristobal Lozano Cabezas, Eduardo Vazquez Ruiz 
de Castroviejo, Juan Munoz Bellido, Maria Eugenia Ruiz; Finland: Seppo Lehto, Kirsti 
Savolainen, Markku Nieminen, Lauri Toivonen, Mikko Syvanne, Mervi Pietila; France: 
Daniel Galley, Christine Beltra, Samuel Levy, Alain Gay, J.C. Daubert, Guillaume Lecocq, 
Christine Poulain; United Kingdom: J.G.F.C. Cleland, Rhidian Shelton, G.Y.H. Lip, A. 
Choudhury; Georgia: Gulnara Abuladze, Irina Jashi; Greece: Dennis V. Cokkinos, Anastasia 
Tsiavou, G. Giamouzis, N. Dagres, A. Kostopoulou, Domproglou, Tsoutsanis, Ch. 
Stefanadis, George Latsios, Ioannis Vogiatzis, Alexandros Gotsis, Paraskevi Bozia, Maria 
Karakiriou, Spyridon Koulouris, John Parissis, George Kostakis, Nikos Kouris, Dimitra 
Kontogianni, Koutroubas Athanasios, Alexandros Douras, Themistoklis Tsanakis, Panos 
Vardas, Mary Marketou, Nikolaos Patsourakos; Hungary: Laszlo Czopf, Robert Halmosi, 
Istvan Preda, Eva Csoti, Andrea Badics; Israel: Boris Strasberg, Nahum A. Freedberg, Amos 
 24 
Katz, Eli Zalzstein, Aviva Grosbard, E. Goldhammer, Menachem Nahir, Menashe Epstein, 
Ida Vider, David Luria, Lori Mandelzweig; Italy: Bruno Aloisi, Alfio Cavallaro, Emanuele 
Antonielli, Baldassarre Doronzo, Diego Pancaldo, Carlo Mazzola, Liliana Buontempi, 
Valeria Calvi, Giuseppe Giuffrida, Antonino Figlia, Francesco Ippolito, Gian-Paolo Gelmini, 
N. Gaibazzi, Virgilio Ziacchi, Francesco De Tommasi, Federico Lombardi, Cesare Fiorentini, 
Paolo Terranova, Pietro Maiolino, Muhamad Albunni, Plinio Pinna-Pintor, Stefano 
Fumagalli, Giulio Masotti, Lorenzo Boncinelli, Domenico Rossi, Giovanni Maria Santoro, 
Massimo Fioranelli, Franco Naccarella, Stefano Sdringola Maranga, Giovannina Lepera, 
Barbara Bresciani, Elena Seragnoli, Mara Cantelli Forti, Valentina  Cortina, Giacinto 
Baciarello, Paolo Cicconetti, Antonio Lax, Federica Vitali, Diran Igidbashian, Luisa 
Scarpino, Sergio Terrazzino, Luigi Tavazzi, Francesco Cantu, Francesco Pentimalli, 
Salvatore Novo, Giuseppe Coppola, Gianluca Zingarini, Giuseppe Ambrozio, Paolo Moruzzi, 
Sergio Callegari, Gabriele Saccomanno, Paolo Russo, Emanuele Carbonieri, Anna Paino, 
Marco Zanetta, Enzo Barducci, Roberto Cemin, Werner Rauhe, Walter Pitscheider, Marina 
Meloni, Sergio Mariano Marchi, Marco Di Gennaro, Sergio Calcagno, Paola Squaratti, 
Francesco Quartili, Patrizia Bertocchi, Mario De Martini, Giuseppe Mantovani, Roman 
Komorovsky, Alessandro Desideri, Leopoldo Celegon, Luigi Tarantini, Giuseppe Catania, 
Donata Lucci, Francesca Bianchini; Lithuania: Aras Puodziukynas, Ausra Kavoliuniene, 
Vilija Barauskiene, Audrius Aidietis, Jurate Barysiene, Vitas Vysniauskas, Irena 
Zukauskiene, Nijole Kazakeviciene; Macedonia: Ljubica Georgievska-Ismail, Lidija 
Poposka; Moldova: Eleonora Vataman, Aurel A. Grosu; The Netherlands: Wilma Scholte 
op Reimer, Esther de Swart, Mattie Lenzen, Jaap Deckers, Chris Jansen, Ritzo Brons, 
Henriette Tebbe, D.C.A van Hoogenhuyze, M.J. Veerhoek, Maria Kamps, D. Haan, 
Nitolanda van Rijn, Annette Bootsma, Leo Baur, Adrie van den Dool, Harry Crijns, Robby 
Nieuwlaat, Heidi Fransen, Luc Eurlings, Joan Meeder, M.J. De Boer, Jobst Winter, Herman 
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Broers, Chris Werter, M. Bijl, Saskia Versluis; Poland: Malgorzata Milkowska, Beata 
Wozakowska-Kaplon, Marianna Janion, Lidia Lepska, Grazyna Swiatecka, Piotr Kokowicz, 
Jacek Cybulski, Aleksandr Gorecki, Marcin Szulc, Jerzy Rekosz, Rafal Manczak, Anna-
Maria Wnuk-Wojnar, M. Trusz-Gluza, Anna Rybicka-Musialik, Jaroslaw Myszor, Michal 
Szpajer, Krzysztof Cymerman, Jerzy Sadowski, Maria Sniezek-Maciejewska, Mariola Ciesla-
Dul, Izabela Gorkiewicz-Kot, Tomasz Grodzicki, Krzysztof Rewiuk, Leszek Kubik, Jacek 
Lewit; Portugal: Joao Manuel Frazao Rodrigues de Sousa, Rafael Ferreira, Antonio Freitas, 
Joao Carlos Araujo Morais, Rui Pires, M.J. Veloso Gomes, Paula Gago, Rui Alexandre C. 
Candeias, Luis Nunes, Joao Vitor Miranda Sa, Miguel Ventura, Mario de Oliveira, Luis 
Brandao Alves; Romania: Ioan Bostaca, Codin T. Olariu, G.A. Dan, Anca Dan, Cristian 
Podoleanu, Attila Frigy, George I.M. Georgescu, Catalina Arsenescu, Cristian Statescu, Radu 
Sascau, Dan L. Dimitrascu, Raluca Rancea; Russian Federation: Yuri V. Shubik, Dmitry 
Duplyakov, Marina Shalak, Vyacheslav Mareev, Marine Danielyan, Albert Galyavich, 
Venera Zakirova; Slovakia: Robert Hatala, Gabriela Kaliska, Jan Kmec; Slovenia: Igor 
Zupan, Jerneja Tasie`, Damijan Vokac; Sweden: Nils Edvardsson, Dritan Poci; Tunisia: 
Habib Gamra, Hichem Denguir; Turkey: Tugrul Okay, Ahmet Sepetoglu, Alev Arat-Ozkan; 
Ukraine: Mariya Orynchak, Elena Paliy, I. Vakalyuk, Oleg Sychov, David Malidze, 
Rostyslav Prog, Myckola Ivanovich Yabluchansky, Nataliya Volodimirovna Makienko; 
Serbia and Montenegro: Tatjana Potpara, Sofija Knezevic, Miomir Randjelovic. 
